New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model

Wenji Zhang,Wenli Cheng,JingHui Li,Zhenrui Huang,Hui Lin,Wenjuan Zhang

DOI: https://doi.org/10.1128/msystems.01027-23

2024-02-29

mSystems

Abstract:ABSTRACT Non-alcoholic fatty liver disease (NAFLD) is a major public health problem due to the high incidence affecting approximately one-third of the world’s population. NAFLD is usually linked to obesity and excessive weight. A subset of patients with NAFLD expresses normal or low body mass index; thus, the condition is called non-obese NAFLD or lean NAFLD. However, patients and healthcare professionals have little awareness and understanding of NAFLD in non-obese individuals. Furthermore, preclinical results from non-obese animal models with NAFLD are unclear. Gut microbiota and their metabolites in non-obese/lean-NAFLD patients differ from those in obese NAFLD patients. Therefore, we analyzed the biochemical indices, intestinal flora, and intestinal metabolites in a non-obese NAFLD mouse model established using a methionine-choline-deficient (MCD) diet. The significantly lean MCD mice had a remarkable fatty liver with lower serum triglyceride and free fatty acid levels, as well as higher alanine transaminase and aspartate transaminase levels than normal mice. 16S RNA sequencing of fecal DNA showed that the overall richness and diversity of the intestinal flora decreased in MCD mice, whereas the Firmicutes:Bacteroidota ratio was increased. g_ Tuzzerella , s_ Bifidobacterium pseudolongum , and s_ Faecalibaculum rodentium were the predominant species in non-obese NAFLD mice. Fecal metabolomics using liquid chromatography-tandem mass spectrometry revealed the potential biomarkers for the prognosis and diagnosis of non-obese NAFLD, including high levels of tyramine glucuronide, 9,12,13-TriHOME, and pantetheine 4′-phosphate, and low levels of 3-carbamoyl-2-phenylpropionaldehyde, N-succinyl-L,L-2,6-diaminopimelate, 4-methyl-5-thiazoleethanol, homogentisic acid, and estriol. Our findings could be useful to identify and develop drugs to treat non-obese NAFLD and lean NAFLD. IMPORTANCE Patients and healthcare professionals have little awareness and understanding of NAFLD in non-obese individuals. In fact, about 40% of people with NAFLD worldwide are non-obese, and nearly one-fifth are lean. Lean NAFLD unfortunately may be unnoticed for years and remains undetected until hepatic damage is advanced and the prognosis is compromised. This study focused on the lean NAFLD, screened therapeutic agents, and biomarkers for the prognosis and diagnosis using MCD-induced male C57BL/6J mice. The metabolites tyramine glucuronide, 9,12,13-TriHOME, and pantetheine 4′-phosphate, together with the predominant flora including g_ Tuzzerella , s_ Bifidobacterium pseudolongum , and s_ Faecalibaculum rodentium , were specific in non-obese NAFLD mice and might be used as targets for non-obese NAFLD drug exploration. This study is particularly significant for non-obese NAFLDs that need to be more actively noticed and vigilant.

microbiology

What problem does this paper attempt to address?

The paper aims to address issues related to non-obese non-alcoholic fatty liver disease (non-obese NAFLD). Specifically, the research focuses on:

1. **Raising Awareness**: Currently, there is a lack of awareness among patients and healthcare professionals about NAFLD in non-obese individuals. Studies show that approximately 40% of NAFLD patients worldwide are non-obese, with nearly 20% being lean. However, these patients are often only discovered when liver damage is severe.

2. **Animal Model Analysis**: Using a methionine-choline-deficient (MCD) diet to establish a non-obese NAFLD mouse model, the study analyzes changes in serum and liver biochemical indicators as well as the gut microenvironment, including alterations in gut microbiota and metabolites.

3. **Diagnostic and Therapeutic Reference**: By studying changes in gut microbiota and their metabolites in the non-obese NAFLD mouse model, the research provides reference data for the diagnosis, treatment, and drug development of NAFLD. The study identifies potential biomarkers such as tyramine glucuronide, 9,12,13-TriHOME, and pantetheine 4'-phosphate, which may aid in the diagnosis and treatment of non-obese NAFLD.

4. **Exploring Drug Targets**: The research identifies several gut microbiota specific to non-obese NAFLD mice, including _g_Tuzzerella_, _s_Bifidobacterium pseudolongum_, and _s_Faecalibaculum rodentium_, which could serve as targets for drug exploration in non-obese NAFLD.

In summary, this study aims to enhance the understanding of non-obese NAFLD and, through animal model experiments, reveal its unique gut microbiota and metabolite characteristics, providing new insights for future diagnosis and treatment.